Medscape July 23, 2021
(Reuters Health) – Chemotherapy patients who receive remote 24-hour monitoring may have better quality of life and better control of symptoms compared to those who receive standard care, a new study suggests.
In an analysis of data from 829 adult patients who had been randomly assigned to receive the 24-hour-monitoring or standard care at their cancer center through multiple cycles of chemotherapy, researchers found that for the intervention group, symptom burden remained at pre-chemotherapy levels, while controls reported an increase from cycle one onwards, according to the report published in The BMJ.
The intervention group participants were tracked with the Advanced Symptom Management System (ASyMS), a mobile based, remote patient monitoring system that provides real time, 24-hour monitoring and management...
Today's Sponsors
Today's Sponsor